UBS AM
RGEN icon

UBS AM’s Repligen RGEN Stock Holding History

UBS AM’s Portfolio RGEN Stock Details RGEN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.1M Sell
161,713
-2,035
-1% -$250K ﹤0.01% 895
2026
Q1 		$19.3M Sell
163,748
-606
-0.4% -$84.7K ﹤0.01% 894
2025
Q4 		$26.9M Sell
164,354
-213
-0.1% -$33.4K 0.01% 758
2025
Q3 		$22M Sell
164,567
-94,004
-36% -$11.4M ﹤0.01% 791
2025
Q2 		$32.2M Buy
258,571
+6,074
+2% +$773K 0.01% 855
2025
Q1 		$32.1M Buy
252,497
+17,154
+7% +$2.64M 0.01% 781
2024
Q4 		$33.9M Buy
235,343
+26,733
+13% +$3.83M 0.01% 763
2024
Q3 		$31M Sell
208,610
-145,254
-41% -$20.8M 0.01% 800
2024
Q2 		$44.6M Buy
353,864
+89,801
+34% +$14.1M 0.01% 643
2024
Q1 		$48.6M Buy
264,063
+1,004
+0.4% +$191K 0.02% 600
2023
Q4 		$47.3M Buy
263,059
+15,614
+6% +$2.43M 0.02% 606
2023
Q3 		$39.3M Buy
247,445
+55,258
+29% +$9.03M 0.02% 622
2023
Q2 		$32.4M Hold
192,187
– – 0.02% 664
2023
Q1 		$32.4M Buy
192,187
+3,410
+2% +$608K 0.02% 664
2022
Q4 		$32M Buy
188,777
+38,736
+26% +$7.03M 0.02% 651
2022
Q3 		$28.1M Sell
150,041
-14,315
-9% -$3.02M 0.02% 680
2022
Q2 		$26.7M Buy
164,356
+2,253
+1% +$356K 0.01% 673
2022
Q1 		$30.5M Sell
162,103
-1,256
-0.8% -$239K 0.01% 732
2021
Q4 		$43.3M Buy
163,359
+312
+0.2% +$84.1K 0.02% 693
2021
Q3 		$47.1M Sell
163,047
-6,199
-4% -$1.59M 0.02% 634
2021
Q2 		$33.8M Sell
169,246
-5,455
-3% -$1.06M 0.01% 741
2021
Q1 		$34M Sell
174,701
-2,138
-1% -$438K 0.02% 717
2020
Q4 		$33.9M Sell
176,839
-5,279
-3% -$960K 0.02% 711
2020
Q3 		$26.9M Buy
182,118
+23,580
+15% +$3.37M 0.01% 689
2020
Q2 		$19.6M Buy
158,538
+13,036
+9% +$1.53M 0.01% 747
2020
Q1 		$14M Buy
145,502
+92,761
+176% +$8.96M 0.01% 777
2019
Q4 		$4.88M Buy
52,741
+5,008
+10% +$421K ﹤0.01% 1200
2019
Q3 		$3.66M Buy
47,733
+7,660
+19% +$670K ﹤0.01% 1334
2019
Q2 		$3.44M Buy
40,073
+7,584
+23% +$517K ﹤0.01% 1352
2019
Q1 		$1.92M Buy
32,489
+3,783
+13% +$218K ﹤0.01% 1540
2018
Q4 		$1.51M Buy
28,706
+1,851
+7% +$109K ﹤0.01% 1548
2018
Q3 		$1.49M Buy
26,855
+2,678
+11% +$138K ﹤0.01% 1625
2018
Q2 		$1.14M Buy
24,177
+5,729
+31% +$236K ﹤0.01% 1768
2018
Q1 		$667K Hold
18,448
– – ﹤0.01% 1915
2017
Q4 		$669K Buy
18,448
+819
+5% +$29.6K ﹤0.01% 1876
2017
Q3 		$676K Buy
17,629
+5,229
+42% +$219K ﹤0.01% 1847
2017
Q2 		$514K Hold
12,400
– – ﹤0.01% 1874
2017
Q1 		$436K Hold
12,400
– – ﹤0.01% 1908
2016
Q4 		$382K Sell
12,400
-10,400
-46% -$322K ﹤0.01% 1874
2016
Q3 		$688K Buy
22,800
+2,300
+11% +$69.4K ﹤0.01% 1827
2016
Q2 		$561K Hold
20,500
– – ﹤0.01% 1903
2016
Q1 		$550K Sell
20,500
-1,100
-5% -$26.9K ﹤0.01% 1879
2015
Q4 		$611K Hold
21,600
– – ﹤0.01% 1946
2015
Q3 		$602K Buy
21,600
+4,400
+26% +$159K ﹤0.01% 1925
2015
Q2 		$710K Buy
17,200
+700
+4% +$25.6K ﹤0.01% 1859
2015
Q1 		$501K Buy
16,500
+600
+4% +$15.6K ﹤0.01% 1981
2014
Q4 		$315K Buy
15,900
+2,600
+20% +$58.1K ﹤0.01% 2201
2014
Q3 		$265K Buy
+13,300
New +$280K ﹤0.01% 2217

Other funds holding RGEN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $18.2B AUM 22.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

UBS AM's RGEN Position: Q2 2026 in Review

UBS AM reduced its Repligen (RGEN) stake by 1.2% in Q2 2026, selling an estimated $250K and leaving 161,713 shares worth $22.1M. The position accounts for ﹤0.01% of the portfolio, ranked #895.

UBS AM first reported a position in RGEN in Q3 2014 and has held it in 48 quarters since. The position peaked at $48.6M in Q1 2024. 482 funds tracked by Wall St. Rank hold RGEN as of Q2 2026.

  • UBS AM held 161,713 shares of Repligen worth $22.1M as of Q2 2026.
  • UBS AM sold 2,035 Repligen shares in Q2 2026, an estimated $250K.
  • Repligen made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #895 holding.
  • UBS AM first reported a position in Repligen in Q3 2014 and has held it in 48 quarters since.
  • UBS AM's Repligen position peaked at $48.6M in Q1 2024.
  • 482 funds tracked by Wall St. Rank held Repligen as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.